The global allergy immunotherapy market is expected to show a significant growth rate during the forecast period. Allergy is hypersensitive to the body’s immune system towards several substances that include pollen, dust, and food. There are various types of allergies includes drugs, food, pollen, latex, and dust among others. As per the Food Allergy Research & Association (FARA), around 15 million people in the US have food allergies and approximately 4% of which is seen in the pediatrics and around more than 60% in adults. The introduction of new immunotherapy drugs and advancement in the treatment and medicine of allergyis the factor fueling the growth of the allergy immunotherapy market during the forecast period.

Request a Free Sample of Our Report on Global Allergy Immunotherapy Market: https://www.omrglobal.com/request-sample/allergy-immunotherapy-market

The rising prevalence of allergies along with growing demand for the treatment of these diseases are motivating the key players of the allergy immunotherapy market to launch technologically advanced and cost-efficient treatment that can be affordable to the large pool of patients. The major market players are actively conducting strategic acquisitions, partnerships, and collaboration to increase their market presence and to gain a competitive edge. For instance, in April 2018, ALK had announced its partnership with Torii Pharmaceutical Co. Ltd. has agreed on a price with authorities and secured a listing on National health Insurance reimbursement for its sublingual allergy immunotherapy tablet against Japanese cedar allergy, brand name CEDAARCURE.

A Full Report of Global Allergy Immunotherapy Market is Available at: https://www.omrglobal.com/industry-reports/allergy-immunotherapy-market

In January 2019, Sandoz, Inc. had announced the introduction of SYMJEPI (epinephrine) 0.3 mg injection for the treatment of allergic reactions (Type 1) in the emergency including anaphylaxis, allergen immunotherapy, drugs, diagnostics testing substance, foods as well as exercise-induced anaphylaxis. The company is introducing this medicine as areasonable, affordable, single-dose and prefilled syringe alternative to epinephrine auto-injectors. In February 2018, Aimmune therapeutics, Biopharmaceutical Company developing a treatment for food allergies, introduced its phase 3 European clinical trial of AR101 for the treatment of peanut allergy that named ARTEMIS met its efficacy endpoint required by the Food and Drug Administration (FDA).

Current Market Trends Covered in the Market Report

Growing cases of allergies across the globe
North America held the largest market share.
Product launch is a key focus of major market players to remain competitive in the market.
Improving healthcare infrastructure in the emerging economies across the globe.

Global Allergy Immunotherapy Market- Segmentation

By Type

Allergic Rhinitis
Allergic Asthma
Food Allergy
Drug Allergy
Others

By Treatment

Subcutaneous Immunotherapy
Sublingual Immunotherapy

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Allergy Immunotherapy Market – Segment by Region

North America

US
Canada

Europe

Germany
UK
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

Latin America
Middle East Africa

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/allergy-immunotherapy-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404